טוען...
Evening and overnight closed-loop control versus 24/7 continuous closed-loop control for type 1 diabetes: a randomised crossover trial
BACKGROUND: Automated closed-loop control (CLC), known as the “artificial pancreas” is emerging as a treatment option for Type 1 Diabetes (T1D), generally superior to sensor-augmented insulin pump (SAP) treatment. It is postulated that evening-night (E-N) CLC may account for most of the benefits of...
שמור ב:
| הוצא לאור ב: | Lancet Digit Health |
|---|---|
| Main Authors: | , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7453908/ https://ncbi.nlm.nih.gov/pubmed/32864597 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2589-7500(19)30218-3 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|